Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

The LINFU® U.S. Registry for the in the General Population Without Risk Factors

Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions.. In this study, LINFU® will be evaluated in the general population with no risk factors and who exhibit no signs or symptoms of disease, This study will help determine if LINFU® can be used to help identify early, asymptomatic pancreatic ductal adenocarcinoma (PDAC) or their precursor lesions (PanIn-2, PanIn-3).

Participants needed: 500
Trial details
Age: 18-90Biological sex: AllType: ObservationalSponsor: Adenocyte, LLCUpdated: Jul 31, 2024Duration: 5 Years
Eligibility criteria

Both males and females will be enrolled and must be at least 18 years of age and... [+4]

Patient under the age of 18 and over the age 90 [+13]

Read more
Status: Not yet recruiting

The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease

Evaluate LINFU® in patients who exhibit signs or symptoms (i.e. jaundice, abdominal pain, weight loss, nausea and vomiting etc.) suggestive of pancreatic cancer (PDAC) or have evidence of imaging studies suggestive of PDAC.

Participants needed: 1,000
Trial details
Age: 18-90Biological sex: AllType: ObservationalSponsor: Adenocyte, LLCUpdated: May 14, 2024Duration: 5 Years
Eligibility criteria

Both males and females will be enrolled and must be at least 18 years of age and... [+3]

Patient under the age of 18 and over the age 90 [+7]

Read more